论文部分内容阅读
染色体易位是大多数慢性粒细胞白血病(CML)的主要发病机制,染色体易位导致断裂点簇集区(breakpoint cluster region,BCR)和酪氨酸激酶ABL1形成融合蛋白。酪氨酸激酶抑制剂伊马替尼(imatinib)可控制CML患者的病程,但是BCR-ABL1 T315I点突变的CML患者对伊马替尼等酪氨酸激酶抑制
Chromosomal translocations are the major pathogenesis of most chronic myeloid leukemia (CML). Chromosomal translocations result in the formation of a fusion protein between breakpoint cluster region (BCR) and tyrosine kinase ABL1. The tyrosine kinase inhibitor imatinib controls the course of CML patients, but the CML patients with the BCR-ABL1 T315I point mutation inhibit tyrosine kinase such as imatinib